FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma

TUESDAY, April 9, 2024-- The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.The approval is for the treatment of...